Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTL-CEBPA + Pembrolizumab in Advanced Solid Tumors
NCT04105335Phase 1Completed
- Sponsor
- Mina Alpha Limited
- Start
- Nov 2019
- Primary completion
- Jan 2025
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label trial of MTL-CEBPA in solid tumor (4 arms), sponsored by Mina Alpha Limited. Primary endpoints: Adverse events at 1 year and Anti-tumour activity at 60 months. Started Nov 2019; status: completed.
02
Drugs
MTL-CEBPA
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04105335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105335.